Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Ark Therapeutics (originally known as Eurogene Limited) was established in July 1997 by three founding scientists,
Professor John Martin, Mr Stephen Barker and Professor Seppo Ylä-Herttuala. The name change took place when Ark
Therapeutics Limited acquired the Finnish company Oy Quattrogene Limited (now known as Ark Therapeutics Oy) in
January 2001. The company's name was further changed, to Ark Therapeutics Group plc, in connection with its Inital
Public Offering in March 2004.